Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Moderna Inc
(NQ:
MRNA
)
89.77
+2.93 (+3.37%)
Streaming Delayed Price
Updated: 11:04 AM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna Inc
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform
April 19, 2022
Moderna's first bivalent booster vaccine candidate, mRNA-1273.211, demonstrated superior neutralizing titers compared to mRNA-1273 against all variants of concern, including Omicron; superiority was...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna to Report First Quarter Financial Results on Wednesday, May 4, 2022
April 13, 2022
CAMBRIDGE, MA / ACCESSWIRE / April 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live...
From
Moderna, Inc.
Via
AccessWire
Jorge Gomez Joins Moderna as Chief Financial Officer
April 11, 2022
CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join...
From
Moderna, Inc.
Via
AccessWire
Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates
April 11, 2022
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle CAMBRIDGE, MA / ACCESSWIRE / April...
From
Moderna, Inc.
Via
AccessWire
IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies
April 07, 2022
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis NEW YORK, NY and CAMBRIDGE, MA / ACCESSWIRE / April 7, 2022 /...
From
Moderna, Inc.
Via
AccessWire
Topics
Death
Exposures
COVID-19
Death
Moderna Launches New Charitable Foundation
April 04, 2022
Initial grants of approximately $5 million awarded to local and global nonprofits that support groups and causes disproportionately affected by COVID-19 CAMBRIDGE, MA / ACCESSWIRE / April 4, 2022 /...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna Launches New Charitable Foundation
April 04, 2022
SOURCE: Moderna
Via
3BL Media
Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273
March 29, 2022
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age CAMBRIDGE, MA / ACCESSWIRE / March 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
March 24, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2022 – USA News Group – Whenever a new COVID-19 variant emergences, health authorities have had limited options to fight...
Via
FinancialNewsMedia
Exposures
COVID-19
Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day
March 24, 2022
- COVID-19 vaccine Phase 2/3 study in children 6 months to under 6 years has successfully met its primary endpoint with robust neutralizing antibody titers similar to adults. Moderna is moving forward...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Moderna Finalizes Strategic Partnership with Australian Government
March 23, 2022
On-shore manufacturing facility based in Melbourne, Australia, expected to produce up to 100 million mRNA respiratory vaccine doses annually CAMBRIDGE, MA / ACCESSWIRE / March 23, 2022 / Moderna, Inc....
From
Moderna, Inc.
Via
AccessWire
Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint
March 23, 2022
- Two 25 μg doses of mRNA-1273 in participants 6 months to under 6 years met primary endpoint with robust neutralizing antibody titers similar to adults mRNA-1273 was generally well tolerated in this...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Moderna Announces New Development Programs Ahead of 3rd Annual Vaccines Day
March 22, 2022
mRNA-1230 is a combination respiratory vaccine candidate against SARS-CoV-2 virus, influenza virus and respiratory syncytial virus (RSV) mRNA-1287 is a vaccine candidate against the four endemic human...
From
ModernaTX, Inc
Via
AccessWire
Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine
March 21, 2022
CAMBRIDGE, MA / ACCESSWIRE / March 21, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.
March 17, 2022
CAMBRIDGE, MA / ACCESSWIRE / March 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted a...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)
March 17, 2022
Announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna's COVID-19 Booster Vaccine
March 16, 2022
CAMBRIDGE, MA / ACCESSWIRE / March 16, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with the...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine
March 14, 2022
CAMBRIDGE, MA / ACCESSWIRE / March 14, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant...
From
Moderna, Inc.
Via
AccessWire
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate
March 10, 2022
Moderna's Omicron-specific bivalent booster candidate (mRNA-1273.214) combines Moderna's Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273) Moderna expects...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna to Host Third Annual Virtual Vaccines Day on March 24, 2022
March 10, 2022
CAMBRIDGE, MA / ACCESSWIRE / March 10, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host its...
From
Moderna, Inc.
Via
AccessWire
Moderna Announces Its Global Public Health Strategy
March 07, 2022
Moderna announces commitment to advance vaccines targeting 15 pathogens identified as biggest public health risk by WHO and CEPI into clinical studies by 2025 Moderna launches mRNA Access, a new...
From
Moderna, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Moderna Announces Memorandum of Understanding with the Government of the Republic of Kenya to Establish its First mRNA Manufacturing Facility in Africa
March 07, 2022
Facility to manufacture drug substance with opportunity for fill/finish and packaging capabilities Moderna investing up to $500 million to produce up to 500 million doses each year for the African...
From
Moderna, Inc.
Via
AccessWire
Moderna Announces Establishment of Enterprise Solutions Hub in Atlanta, Georgia
March 03, 2022
The Americas Enterprise Solutions Hub will support the U.S., Canada and Latin America and is in addition to Moderna's International Enterprise Solutions Hub in Warsaw, Poland Atlanta selected due to...
From
Moderna, Inc.
Via
AccessWire
Moderna to Present at Upcoming Conferences in March 2022
March 02, 2022
CAMBRIDGE, MA / ACCESSWIRE / March 2, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the...
From
Moderna, Inc.
Via
AccessWire
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union
February 24, 2022
Announcement follows CHMP's previous decision to adopt a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include adolescents 12 years of age and older....
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates
February 24, 2022
Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29 Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of...
From
Moderna, Inc.
Via
AccessWire
Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration
February 23, 2022
From
Thermo Fisher Scientific Inc. and Moderna, Inc.
Via
Business Wire
Moderna Expands Global Footprint Through Commercial Partnership with Adium in Latin America
February 22, 2022
Moderna has a commercial footprint in 56 countries across the world through direct presence and distributors and plans expansion in ten additional markets in 2022 Moderna also supplies the Company's...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
February 22, 2022
Endorsement to proceed given by the independent Data and Safety Monitoring Board based on preliminary Phase 2 safety and tolerability data Moderna expects to enroll approximately 34,000 participants in...
From
Moderna, Inc.
Via
AccessWire
Moderna Expands Its mRNA Pipeline with Three New Development Programs
February 18, 2022
mRNA-1608 is a vaccine candidate against Herpes simplex virus (HSV) mRNA-1468 is a vaccine candidate against varicella-zoster virus (VZV) to reduce the rate of herpes zoster (shingles) mRNA-4359 is a...
From
Moderna, Inc.
Via
AccessWire
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.